Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724376 | 0.86 | TSHR (0.45) | TSHRHSD17B10MIFLMNATP53 | |
| SCHEMBL5724370 | 0.85 | TSHR (0.43) | TSHRHSD17B10MIFLMNATP53 | |
| SCHEMBL5724065 | 0.83 | KDM4E (0.55) | MIFLMNATP53POLBKDM4E | |
| SCHEMBL5724346 | 0.80 | HPGD (0.61) | TSHRHSD17B10LMNATP53KDM4E | |
| SCHEMBL5723872 | 0.79 | HSD17B10 (0.42) | TSHRHSD17B10MIFLMNAKDM4E | |
| SCHEMBL5724236 | 0.77 | HRH3 (0.36) | LMNAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL5724121 | 0.72 | KDM4E (0.55) | TSHRLMNAKDM4ESMN1; SMN2HPGD | |
| SCHEMBL5723878 | 0.71 | HSD17B10 (0.41) | TSHRHSD17B10MIFLMNAKDM4E | |
| SCHEMBL5724213 | 0.71 | KDM4E (0.49) | MIFLMNATP53KDM4ENPC1 | |
| SCHEMBL5724279 | 0.71 | HRH3 (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | TSHR 4873/4885HSD17B10 259/4885MIF 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.